Centessa Pharmaceuticals

IPO

Homepage

Public · United States · Founded 2021 · $550.0M raised

Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$550.0M
Last Round
$300.0M Corporate RoundApr 2024
Rounds
2
Type
Public

About

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company built on an asset-centric R&D model, formed through the merger of multiple biotech companies to pursue first-in-class and best-in-class medicines. Its pipeline spans discovery-stage to late-stage programs in neuroscience, including an orexin receptor 2 (OX2R) agonist program for sleep-wake disorders and its proprietary LockBody antibody technology platform. In 2026 Centessa agreed to be acquired by Eli Lilly and Company for up to $7.8 billion.

Summary

Centessa Pharmaceuticals is a Healthcare company based in United States, founded in 2021. It has raised $550.0M in total across 2 rounds, most recently a $300.0M Corporate Round round in Apr 2024. Investors include General Atlantic and EcoR1 Capital.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Corporate RoundCorporate RoundApr 2024
$300.0M

Sign up to see all 3 rounds

Series A through Corporate Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Centessa Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/centessa-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/centessa-pharmaceuticals" alt="Centessa Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>